GenSight Biologics S.A.
GSGTF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.04M
Close$
$-0.08
198.6% downside
Current Fair Value
198.6% downsideOvervalued by 198.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $13.04 Million |
|---|---|
| Enterprise Value | $24.98 Million |
| Earnings per Share | $-0.08 |
| Beta | 0.73 |
| Outstanding Shares | 223,080,815 |
Return
| Return on Equity | 90.60% |
|---|---|
| Return on Assets | -471.66% |
| Return on Invested Capital | 539.60% |
Valuation & Multiples
| P/E Ratio | -0.96 |
|---|---|
| PEG | -2.03 |
| Price to Sales | -0.08 |
| Price to Book Ratio | -0.08 |
| Enterprise Value to Revenue | -80.07 |
| Enterprise Value to EBIT | -0.86 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.54 |
| Debt to Equity | -0.4 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 29, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About GenSight Biologics S.A.
13 employees
CEO: Laurence Rodriguez
GenSight Biologics S.A. is a clinical-stage biotechnology firm dedicated to pioneering, advancing, and bringing to market treatments for serious eye and central nervous system disorders, specifically those linked to mitochondrial dysfunc...